WGSGeneDx Holdings Corp.
Services-Health Services
- Revenue
- $428M
- 40% YoY
- Operating margin
- -3.1%
- 60% YoY
- EBITDA
- −$3M
- 77% YoY
- Market cap
- $2.1B
- Employees
- —
- Net debt / EBITDA
- —
- $40M net debt
- AI in 10-K
- 5.3
- mentions per 10K words
Takeover score 3 of 13
Fixable underperformance 1 of 7
- TSR below peersNo1 of 3 years3+ of last 5 years
- High CEO pay despite TSRNo$4M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo8% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo0% of assetsOver 40% of assets
- Shareholder dissentYes76% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo5.3 per 10K words · 83rd pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$2.1B market capMarket cap $500M–$5B
Catalysts 1 of 2
- Active 13DYes1 filingActive-intent 13D in 18 months
- Net insider sellingNo$85M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $212M | $235M | $203M | $305M | $428M | 40% |
| Operating income | −$446M | −$668M | −$181M | −$23M | −$13M | 44% |
| Net income | −$245M | −$549M | −$176M | −$52M | −$21M | 60% |
| Operating cash flow | −$190M | −$319M | −$180M | −$28M | $33M | 217% |
| Capex | $9M | $7M | $5M | $5M | $19M | 246% |
| Stock-based comp | $219M | $42M | −$326K | $9M | $32M | 252% |
Deal filings
| Filed | Form | Acquirer | Price | Premium |
|---|---|---|---|---|
| Mar 31, 2022 | DEFM14A | Sema4 Holdings Corp. | $80000000.00 | 80% |
| Mar 15, 2022 | PREM14A | — | $4.86 | 10.83% |
| Jul 2, 2021 | DEFM14A | Mount Sinai Genomics, Inc. d b a Sema4 | $10.00 | 0% |
| May 6, 2021 | PREM14A | Mount Sinai Genomics, Inc. d b a Sema4 | $10.00 | 100% |
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| May 22, 2026 | CMLS Holdings LLC | SCHEDULE 13D/A | 45.7% | Active |
| May 15, 2026 | CMLS Holdings LLC | SCHEDULE 13D/A | 1.8% | Passive |
| May 11, 2026 | CMLS Holdings LLC | SCHEDULE 13D/A | 1.8% | Passive |
| Aug 26, 2025 | CMLS Holdings LLC | SCHEDULE 13D/A | 1.9% | Passive |
| May 7, 2025 | CMLS Holdings LLC | SCHEDULE 13D/A | 1.9% | Passive |
| Feb 21, 2025 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | SCHEDULE 13D/A | 4.9% | Passive |
| Feb 18, 2025 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | SCHEDULE 13D/A | 6.1% | Passive |
| Nov 19, 2024 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | SC 13D/A | 9.9% | Passive |
| Nov 4, 2024 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | SC 13D/A | 10.4% | Passive |
| May 31, 2024 | CMLS Holdings LLC | SC 13D/A | 2.1% | Passive |
Insider trading
- Open-market buys, 12 mo
- $107M · 34
- Open-market sells, 12 mo
- $21M · 105
- Net
- $85M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $14M | $43M | 1494 | 139 |
| FY2024 | $4M | $52M | 883 | 104 |
| FY2023 | $4M | $546K | 32 | 105 |